Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.

Bao Sun; Jiang Li; Shuyang Sun; Chunye Zhang; Jingjing Sun; Shengming Xu; Yu Wang; Ronghui Xia

Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.

Bao Sun(Shanghai Jiao Tong University), Jiang Li(Shanghai Jiao Tong University), Shuyang Sun(Guangxi Medical University), Chunye Zhang(National Clinical Research Center for Digestive Diseases), Jingjing Sun(ITRI International), Shengming Xu(Shanghai Jiao Tong University), Yu Wang(Shanghai Jiao Tong University), Ronghui Xia(Shanghai Jiao Tong University)

PubMed

January 1, 2021

Cited by 13

|Cell Research|2015|243

Nanomaterials for Cancer Precision Medicine

|Advanced Materials|2018|212

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

|International Journal of Nanomedicine|2021|141

Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies

|Cell Metabolism|2022|135

Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

|Clinical Cancer Research|2019|131

Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.

Related Papers